"13 Spike 02" principal and interest payment and delisting announcement.
Release time:
2021-05-20
股票代码:600668 股票简称:尖峰集团 公告编号:临2019-035
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
“13尖峰02”本息兑付和摘牌公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
- 兑付债权登记日:2019年11月19日
- 债券停牌起始日:2019年11月20日
- 兑付资金发放日:2019年11月20日
- 摘牌日:2019年11月20日
浙江尖峰集团股份有限公司2013年公司债券(第二期)(以下简称“本期债券”)将于2019年11月20日开始支付2018年11月20日至2019年11月19日期间最后一个年度利息和本期债券的本金,为保证还本付息工作的顺利进行,现将有关事宜公告如下:
一、本期债券基本情况
1、债券名称:浙江尖峰集团股份有限公司2013年公司债券(第二期)。
2、债券简称及代码:13尖峰02,代码122344
3、发行人:浙江尖峰集团股份有限公司
4、发行规模:本期债券发行总额为人民币3亿元。根据《浙江尖峰集团股份有限公司公开发行公司债券(第二期)募集说明书》中所设定的投资者回售选择权条款,本期债券在回售登记期(2017年10月13日至2017年10月19日)进行回售申报登记,有效登记数量为46,300手,回售金额为4,630万元。2017年11月20日,公司已经支付了回售款,公司本期债券余额为25,370万元。
5、债券期限:本期债券的期限为5年(附第3年末发行人上调票面利率选择权和投资者回售选择权)。
6、债券发行批准机关及文号:中国证券监督管理委员会证监许可[2013]595号文件批准发行。
7、债券形式:实名制记账式
8、债券利率:本期债券票面利率为5.09%,采用单利按年计息,不计复利。每年付息一次,到期一次还本,最后一期利息随本金的兑付一起支付。
9、计息期限:本期债券计息期限自2014年11月20日至2019年11月19日止;若投资者行使回售选择权,则回售部分债券的计息期限自2014年11月20日至2017年11月19日止。
10、付息日:本期债券付息日为2015年至2019年每年的11月20日;若投资者行使回售选择权,则回售部分债券的付息日为2014年至2017年每年的11月20日(上述付息日如遇法定节假日,则顺延至下一个工作日;每次付息款项不另计利息)。
11、兑付日:本期债券兑付日为2019年11月20日;若投资者行使回售选择权,则回售部分债券的兑付日为2017年11月20日(上述兑付日如遇法定节假日,则顺延至下一个工作日,每次兑付款项不另计利息)。
12、信用级别:经联合信用评级有限公司综合评定,本期公司债券信用等级为AA+,发行人主体信用等级为AA。
13、上市时间和地点:本期债券于2014年12月11日在上海证券交易所上市交易。
14、负责债券登记、托管、委托债券派息和兑付的机构:中国证券登记结算有限责任公司上海分公司
二、本次本息兑付方案
根据公司《浙江尖峰集团股份有限公司公开发行公司债券(第二期)募集说明书》和《浙江尖峰集团股份有限公司2013年公司债券(第二期)票面利率公告》的约定,本期债券的票面利率为5.09%,每手“13尖峰02”(面值人民币1,000元)实际派发利息为人民币50.90元(含税),兑付本金为1,000元(含税)。本次兑付的本息总额为266,613,330.00元(含税)。
三、兑付债权登记日及兑付日
1、兑付债权登记日:2019年11月19日
2、债券停牌起始日:2019年11月20日
3、兑付资金发放日:2019年11月20日
4、摘牌日:2019年11月20日
四、兑付对象
本次兑息兑付对象为截止2019年11月19日下午上海证券交易所收市后,在中国证券登记结算有限责任公司上海分公司(以下简称“中证登上海分公司”)登记在册的全体“13尖峰02”公司债券的持有人。
五、兑付、兑息办法
(1)本公司已与中证登上海分公司签订了《委托代理债券兑付、兑息协议》,委托中证登上海分公司进行债券兑付、兑息。公司将在兑付资金发放日前第二个交易日16:00前将本期债券本金及利息足额划付至中证登上海分公司指定的银行账户。如本公司未按时足额将债券兑付、兑息资金划入中证登上海分公司指定的银行账户,则中证登上海分公司将根据协议终止委托代理债券兑付、兑息服务,后续兑付、兑息工作由本公司自行负责办理,相关实施事宜以本公司的公告为准。
(2)中证登上海分公司在收到款项后,通过资金结算系统将债券本金及利息 划付给相应的兑付机构(证券公司或中证登上海分公司认可的其他机构),投资者于兑付机构领取债券本金及利息。
六、关于投资者缴纳本期债券利息所得税的说明
(一)关于向个人投资者征收企业债券利息所得税的说明
根据《中华人民共和国个人所得税法》以及其他相关税收法规和文件的规定,本期债券个人投资者应缴纳公司债券个人利息收入所得税。本期债券利息个人所得税将由各兑付机构负责代扣代缴,并直接向各兑付机构所在地的税务部门缴付。本期债券的个人利息所得税征缴说明如下:
1、纳税人:本期债券的个人投资者;
2、征税对象:本期债券的利息所得;
3、征税税率:按利息额的20%征收;
4、征税环节:个人投资者在兑付机构领取利息时由兑付机构一次性扣除;
5、代扣代缴义务人:负责本期债券付息工作的各兑付机构。
6、本期债券利息税的征管部门:各兑付机构所在地的税务部门。
(二)关于向非居民企业征收企业债券利息所得税的说明
根据2018年11月7日发布的《关于境外机构投资境内债券市场企业所得税增值税政策的通知》,自2018年11月7日起至2021年11月6日止,对境外机构投资境内债券市场取得的债券利息收入暂免征收企业所得税和增值税。上述暂免征收企业所得税的范围不包括境外机构在境内设立的机构、场所取得的与该机构、场所有实际联系的债券利息。
(三)其他投资者缴纳公司债券利息所得税的说明
对于本期债券其他投资者,其债券利息所得税自行缴纳。
七、本期债券兑付相关机构
1、发行人:浙江尖峰集团股份有限公司
住所:浙江省金华市婺江东路88号
法定代表人:蒋晓萌
联系人:朱坚卫、余果
联系电话:0579-82320582、82324699
传真:0579-82320582、82324699
2、主承销商:浙商证券股份有限公司
法定代表人:吴承根
住所:杭州市江干区五星路201号
联系人:华佳、马岩笑
联系电话:0571-87902082、87903124
传真:0571-87903239
3、托管人:中国证券登记结算有限责任公司上海分公司
地址:上海市陆家嘴东路166号中国保险大厦3层
联系人:徐瑛
电话:021-68870114
传真:021-68875802
邮政编码:200120
特此公告。
浙江尖峰集团股份有限公司
董 事 会
二〇一九年十一月十一日
More information
The company fully deploys 2018 work
On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-30
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise
On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31